Two Rebeccamycin Analogue Regimens in Treating Patients With Advanced or Recurrent Non-small Cell Lung Cancer

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically proven stage IIIB (with pleural effusions), IV, or recurrent non-small cell lung cancer with failure on 1 prior chemotherapy regimen
• Measurable disease
• PATIENT CHARACTERISTICS:
• Age:
• Not specified
• Performance status:
• 0-2
• Life expectancy:
• At least 12 weeks
• Hematopoietic:
• WBC at least 3,000/mm\^3
• Granulocyte count at least 1,500/mm\^3
• Platelet count at least 100,000/mm\^3
• Hemoglobin greater than 10 g/dL
• Hepatic:
• Bilirubin no greater than 1.5 mg/dL
• AST and ALT less than 2 times normal
• Renal:
• Creatinine normal OR
• Creatinine clearance at least 60 mL/min
• Cardiovascular:
• No New York Heart Association class III or IV heart disease
• Other:
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• No concurrent illness that would preclude study
• PRIOR CONCURRENT THERAPY:
• Biologic therapy:
• Not specified
• Chemotherapy:
• See Disease Characteristics
• No more than 1 prior chemotherapy regimen
• At least 4 weeks since prior chemotherapy
• Endocrine therapy:
• Not specified
• Radiotherapy:
• Not specified
• Surgery:
• Not specified
• Other:
• No concurrent combination antiretroviral therapy for HIV